Last update 22 Jun 2024

Naproxen

Last update 22 Jun 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(+)-(S)-6-Methoxy-α-methyl-2-naphthaleneacetic acid, (+)-(S)-Naproxen, (+)-2-(6-Methoxy-2-naphthyl)propionic acid

+ [37]

Target

COX

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesNervous System Diseases+ [4]

Active Indication

PainGoutInflammation+ [5]

Inactive Indication

Breast CancerLow Back PainOstealgia+ [2]

Originator Organization

Atnahs Pharma UK Ltd.

Active Organization

Atnahs Pharma US Ltd.

Hubei Huazhong Pharmaceutical Co. Ltd.

Bayer AG

+ [1]

Inactive Organization

Amgen, Inc.

Iroko Pharmaceuticals LLC

Oxford Pharmascience Ltd.

+ [1]

Drug Highest PhaseApproved

First Approval Date

US (11 Mar 1976),

Ankylosing SpondylitisJuvenile ArthritisOsteoarthritis+ [1]

Regulation-

Structure

Molecular FormulaC14H14O3

InChIKeyCMWTZPSULFXXJA-VIFPVBQESA-N

CAS Registry22204-53-1

162

Clinical Trials associated with Naproxen

NCT06453291 / RecruitingNot ApplicableIIT

Innovative Approaches in Managing Chronic Low Back Pain: A Comparative Assessment of Clinical Techniques

This clinical trial aims to assess the effectiveness of different clinical techniques in treating patients with chronic low back pain (CLBP). Two test groups will be included: one receiving conventional therapy (NSAIDs and other physical therapy techniques) and the other receiving a combination of neuromodulation and platelet-rich plasma (PRP) therapy. Chronic pain, persisting for more than three months, inhibits natural pathways like GABA and promotes excitatory pathways, leading to increased inflammation. The study hypothesizes that neuromodulation via the dorsal root ganglion (DRG) and PRP therapy will provide superior pain relief and functional improvement compared to conventional therapy.

Start Date01 Jul 2024

Sponsor / Collaborator-

IRCT20130313012810N27 / Completed

Comparative bioequivalence study of the Naproxen 250 mg, tablet manufactured by Daana Pharma Company

Start Date09 May 2024

Sponsor / Collaborator

Daana Pharmaceutical Co.

NCT06274151 / Not yet recruitingNot ApplicableIIT

Optimal Treatment of Inflammation Following Acute Skeletal Muscle Injury

Acute muscle strain injuries occur both during sports, in leisure time activities and during manual occupation and represent a major clinical challenge and has societal economic costs. The recovery time is long and a substantial injury recurrence is observed. Despite current best evidence rehabilitation with early mechanical loading, a significant loss of muscle mass, fatty infiltration and formation of scar tissue is reported.
Animal models and human in vitro experiments suggest that inflammation is vital in the early period after an injury, however an inhibition of inflammatory processes is beneficial for healing.
We investigate here whether a pharmacological inhibition of inflammatory pathways in the 2nd week following a muscle strain injury will provide a better clinical outcome and an advantageous cellular profile than rehabilitative training alone would.

Start Date15 Feb 2024

Sponsor / Collaborator

Bispebjerg Hospital

100 Clinical Results associated with Naproxen

100 Translational Medicine associated with Naproxen

100 Patents (Medical) associated with Naproxen

6,438

Literatures (Medical) associated with Naproxen

31 Dec 2024·Journal of the International Society of Sports Nutrition

The dose-response effects of flurbiprofen, indomethacin, ibuprofen, and naproxen on primary skeletal muscle cells

Article

Author: Roberts, Brandon M ; Matheny, Ronald W ; Geddis, Alyssa V

BACKGROUND:

Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, flurbiprofen, naproxen sodium, and indomethacin are commonly employed for their pain-relieving and inflammation-reducing qualities. NSAIDs work by blocking COX-1 and/or COX-2, enzymes which play roles in inflammation, fever, and pain. The main difference among NSAIDs lies in their affinity to these enzymes, which in turn, influences prostaglandin secretion, and skeletal muscle growth and regeneration. The current study investigated the effects of NSAIDs on human skeletal muscle cells, focusing on myoblast proliferation, differentiation, and muscle protein synthesis signaling.

METHODS:

Using human primary muscle cells, we examined the dose-response impact of flurbiprofen (25-200 µM), indomethacin (25-200 µM), ibuprofen (25-200 µM), and naproxen sodium (25-200 µM), on myoblast viability, myotube area, fusion, and prostaglandin production.

RESULTS:

We found that supraphysiological concentrations of indomethacin inhibited myoblast proliferation (-74 ± 2% with 200 µM; -53 ± 3% with 100 µM; both p < 0.05) compared to control cells and impaired protein synthesis signaling pathways in myotubes, but only attenuated myotube fusion at the highest concentrations (-18 ± 2% with 200 µM, p < 0.05) compared to control myotubes. On the other hand, ibuprofen had no such effects. Naproxen sodium only increased cell proliferation at low concentrations (+36 ± 2% with 25 µM, p < 0.05), and flurbiprofen exhibited divergent impacts depending on the concentration whereby low concentrations improved cell proliferation (+17 ± 1% with 25 µM, p < 0.05) but high concentrations inhibited cell proliferation (-32 ± 1% with 200 µM, p < 0.05).

CONCLUSION:

Our findings suggest that indomethacin, at high concentrations, may detrimentally affect myoblast proliferation and differentiation via an AKT-dependent mechanism, and thus provide new understanding of NSAIDs' effects on skeletal muscle cell development.

01 Mar 2024·International journal of pharmaceutics

Tailoring the use of excipients in bottom-up production of naproxen crystal suspensions via membrane technology

Article

Author: De Witte, Bruno ; Anjum, Fatima ; Wessner, Maximilian ; Sadowski, Gabriele ; Al-Rifai, Noor ; Collas, Alain

Long-acting crystal suspensions of active pharmaceutical ingredients (API) mostly comprised of an API, a suspension media (water) and excipients and provide sustained API release over time. Excipients are crucial for controlling particle size and to achieve the stability of the API crystals in suspension. A bottom-up process was designed to produce long-acting crystal suspensions whilst investigating the excipient requirements during the production process and the subsequent storage. PVP K30 emerged as the most effective excipient for generating stable naproxen crystals with the desired size of 1 to 15 μm, using ethanol as solvent and water as anti-solvent. Calculations, performed based on the crystal properties and assuming complete PVP K30 adsorption on the crystal surface, revealed lower PVP K30 requirements during storage compared to initial crystal generation. Consequently, a membrane-based diafiltration process was used to determine and fine-tune PVP K30 concentration in the suspension post-crystallization. A seven-stage diafiltration process removed 98 % of the PVP K30 present in the suspension thereby reducing the PVP-to-naproxen ratio from 1:2 to 1:39 without impacting the stability of naproxen crystals in suspension. This work provides insights into the excipient requirements at various production stages and introduce the membrane-based diafiltration for precise excipient control after crystallization.

01 Mar 2024·Naunyn-Schmiedeberg's archives of pharmacology

Peroxisome proliferator activated receptor-gamma (PPAR-γ) ligand, pioglitazone, increases analgesic and anti-inflammatory effects of naproxen

Article

Author: Cheraghi-Poor, Mohammad ; Haddadi, Rasool

The aim of this study was the investigation of analgesic and anti-inflammatory activity of naproxen and pioglitazone following intra-plantar injection of carrageenan and assessment of the PPAR-γ receptor involvement in these effects. Rats were intra-plantarly injected with carrageenan (1%, 100 μl) to induce thermal hyperalgesia and paw inflammation. Different groups of rats were pre-treated intraperitoneally with naproxen (1 and 10 mg/kg) or pioglitazone (3 and 10 mg/kg) or GW9662 (a selective PPAR-γ antagonist, 100 μl/paw). The volume of the paw was evaluated using a plethysmometer, and the hot plate test was employed to assess the pain threshold in the animals. Finally, TNF-α, IL-1ß, IL-6, and myeloperoxidase (MPO) activity status were evaluated in the hind paw tissue. Naproxen and pioglitazone demonstrated analgesic and anti-inflammatory activity. Concurrent injection of an ineffective dose of naproxen (1 mg/kg) with an ineffective dose of pioglitazone (3 mg/kg) caused augmented analgesic and anti-inflammatory activity, significantly (p≤0.001 and p≤0.01, respectively). Additionally, intra-plantar injection of GW-9662 before naproxen or pioglitazone significantly suppressed their analgesic (p≤0.001) and anti-inflammatory activity (p≤0.01). Also, naproxen and pioglitazone (10 mg/kg) significantly (p≤0.001) reduced carrageenan-induced MPO activity and TNF-α, IL-6, and IL-1ß releasing. Furthermore, PPAR-γ blockade significantly prevented suppressive effects of naproxen and pioglitazone on the MPO activity and inflammatory cytokines. Pioglitazone significantly increased analgesic and anti-inflammatory effects of naproxen. This study proposes that concurrent treatment with naproxen and pioglitazone may be a substitute for overcome pain and inflammation clinically, in the future, particularly in patients with cardiovascular disorders and diabetes.

News (Medical) associated with Naproxen

29 May 2024

·www.biospace.com

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

SAN DIEGO, May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior Approval Supplement ("PAS") submission to the U.S. Food and Drug Administration ("FDA") for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN"). Heron expects to receive the assigned action date for completion of the FDA's review of this PAS within the next several weeks and anticipates an action date on this PAS to be between four (4) and six (6) months. The ZYNRELEF kit contains a ready-to-use vial and all necessary components for needle-free application to the patient. The current kit contains a vented vial spike ("VVS") which can take up to three (3) minutes to complete product withdrawal, requiring coordination between both sterile and nonsterile personnel. If approved, the introduction of the VAN will replace the VVS and has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time down to twenty (20) – forty-five (45) seconds. The user-friendly "container-like" design of the VAN may enhance the safe use of ZYNRELEF, increase adoption, and improve the preparation process. "This VAN submission for ZYNRELEF directly addresses feedback Heron has received from healthcare providers around the need to improve the preparation of ZYNRELEF for use. We are excited that this has the potential to simplify preparation and introduce a more streamlined process for our clinicians, allowing for more patients to experience significant pain relief following surgery," said Dr. Bill Forbes, Executive Vice President, Chief Development Officer at Heron. ZYNRELEF is the first and only therapy for postoperative pain management to be rigorously tested in Phase 3 studies and demonstrate superiority to bupivacaine solution, the current standard-of-care. ZYNRELEF demonstrated superiority compared to bupivacaine with lower pain scores, fewer patients experiencing severe pain, and lower opioid consumption. ZYNRELEF was initially approved by the FDA in May 2021, received approval of the first supplemental New Drug Application ("sNDA") for an expanded label in December 2021, followed by the second sNDA for an expanded label in January 2024. Important Safety Information for Patients ZYNRELEF contains an NSAID (non-steroidal anti-inflammatory drug), a type of medicine which: can increase the risk of a heart attack or stroke that can lead to death. This risk increases with higher doses and longer use of an NSAID. cannot be used during heart bypass surgery. can increase the risk of gastrointestinal bleeding, ulcers, and tears. ZYNRELEF should also not be used: if you are allergic to any component of ZYNRELEF, similar local anesthetics, aspirin or other NSAIDs (such as ibuprofen or naproxen), or have had an asthma attack, hives, or other allergic reaction after taking any of these medicines. as a paracervical block, during childbirth. The most common side effects of ZYNRELEF are soft tissue procedures: vomiting and orthopedic procedures: constipation and headache. The medicines in ZYNRELEF (a local anesthetic and an NSAID) may affect the nervous and cardiovascular system; may cause liver or kidney problems; may reduce the effects of some blood pressure medicines; should be avoided if you have severe heart failure; may cause adverse effects on cartilage; may cause a rare blood disorder, or life-threatening skin or allergic reactions; may harm your unborn baby if received at 20 weeks of pregnancy or later; and may cause low red blood cells (anemia). Tell your healthcare provider about all your medical conditions and about all the medicines you take including prescription or over-the-counter medicines, vitamins, or herbal supplements to discuss if ZYNRELEF is right for you. Talk to your healthcare provider for medical advice about side effects. Report side effects to Heron at 1-844-437-6611 or to FDA at 1-800-FDA-1088 or . The information provided here is not comprehensive. Please see full Prescribing Information, including Boxed Warning. About ZYNRELEF for Postoperative Pain ZYNRELEF is the first and only dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam. ZYNRELEF is the first and only extended-release local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and significantly increased proportion of patients requiring no opioids through the first 72 hours following surgery compared to bupivacaine solution, the current standard-of-care local anesthetic for postoperative pain control. ZYNRELEF was initially approved by the U.S. Food and Drug Administration (the "FDA") in May 2021 for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty. In December 2021, the FDA approved an expansion of ZYNRELEF's indication to include foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures. On January 23, 2024, the FDA approved ZYNRELEF for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures. Please see full prescribing information, including Boxed Warning, at . About Heron Therapeutics, Inc. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit . Forward-looking Statements This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding the potential market opportunities for ZYNRELEF, APONVIE, CINVANTI and SUSTOL; revenue, adjusted EBITDA and other financial guidance provided by the Company; the results of the commercial launch of APONVIE; the potential additional market opportunity for the expanded U.S. label for ZYNRELEF; the timing of the Company's development of the VAN program and receipt of required regulatory approvals; our ability to establish and maintain successful commercial arrangements like our co-promotion agreement CrossLink Life Sciences; the outcome of the Company's pending ANDA litigation; whether the Company is required to write-off any additional inventory in the future; the expected future balances of Heron's cash, cash equivalents and short-term investments; the expected duration over which Heron's cash, cash equivalents and short-term investments balances will fund its operations and the risk that future equity financings may be needed; any inability or delay in achieving profitability. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law. Investor Relations and Media Contact: Ira Duarte Executive Vice President, Chief Financial Officer Heron Therapeutics, Inc. iduarte@herontx.com 858-251-4400 View original content: SOURCE Heron Therapeutics, Inc. Company Codes: NASDAQ-SMALL:HRTX

Phase 3Drug ApprovalClinical Result

12 Apr 2024

·www.sciencedaily.com

A third of women experience migraines associated with menstruation, most commonly when premenopausal

A third of the nearly 20 million women who participated in a national health survey reports migraines during menstruation, and of them, 11.8 million, or 52.5%, were premenopausal. A third of the nearly 20 million women who participated in a national health survey report migraines during menstruation, and of them, 11.8 million, or 52.5%, were premenopausal. The analysis was conducted by researchers at Georgetown University Medical Center and Pfizer, Inc., which makes a migraine medication. Because of the underuse of medications to help treat or prevent menstrual migraines, investigators wanted to understand how common menstrual migraines were and which groups of women could most benefit from potential therapies. The study will be presented April 16, at the American Academy of Neurology 2024 Annual Meeting in Denver. "The first step in helping a woman with menstrual migraine is making a diagnosis; the second part is prescribing a treatment; and the third part is finding treatments patients are satisfied with and remain on to reduce disability and improve quality of life," says the study author, Jessica Ailani, MD, professor of clinical neurology at Georgetown University School of Medicine and director of the MedStar Georgetown Headache Center at Medstar Georgetown University Hospital. The researchers used the 2021 U.S. National Health and Wellness Survey, conducted by the National Center for Health Statistics, to analyze responses from women who reported their current migraine treatments, frequency and disabilities via the Migraine Disability Assessment Test (MIDAS), a five-question survey. A migraine headache can cause severe throbbing pain or a pulsing sensation, usually on one side of the head. It's often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. "Discrepancies in the incidence of who gets migraine attacks associated with menses is likely due to premenopausal women having more regular menstrual cycles and thus more menstrual-related migraines," says Ailani. "Additionally, as women move into their 40's and become peri-menopausal, there tends to be a greater shift through the month in hormone levels also leading to frequent migraine attacks." The survey found that for all women during their menstrual periods, migraine attacks occurred as frequently as 4.5 times and that monthly only migraine headaches lasted 8.4 days, on average; 56.2 % of women had moderate-to-severe migraine-specific disabilities that ranked highest on the MIDAS scale. When looking at treatments women in the survey used to help control their migraine symptoms, 42.4% used over-the-counter medications while 48.6% used prescription medications. Of the 63.9 % of women who used migraine treatments for acute symptoms, the most commonly used were triptans, a class of drugs developed in the 1990s to quiet overactive nerves associated with migraines and cluster headaches. Sara's story Sara, a 38 year old mother of two, says her migraines are predictably and consistently worse during her period. "It definitely disrupts my ability to go about my normal activities including at work," Sara says. "I'm pretty lucky that I'm generally responsive to prescription medication, but I often still have to lie down for an hour or so while the medicine kicks in." Sara is being treated preventatively for migraines with Botox. She says over the past couple of months, she's had a couple of migraines outside of when she gets her period, but that the headaches are definitely worse during menstruation. "While I had my last period, I had a migraine every day for a week," Sara says. "It's starkly different [during menstruation]." Prevention Possibilities Non-steroidal anti-inflammatory drugs (NSAIDs), such as naproxen or ibuprofen, are sometimes used as preventive medications for women with regular menstrual periods. In this study, 21.1% of women reported use of any migraine prevention medications or therapies. "Preventive treatments are used less frequently than acute treatment for migraine," Alaini said. "In my opinion, this is because preventive therapy is a long-term commitment by both a woman and her clinician to improving the disease process. Migraine is a life-long brain disease without a cure, and the goal of preventive therapy is to reduce disease burden and improve quality of life. Unfortunately, newer disease-specific treatments are costly, so generic older treatments are often used and come with greater side effects." Next Steps The researcher's next steps involve looking at larger databases to see if they can mimic findings on a global scale. They want to determine if women with menstrual-related migraine are frequently turning to non-migraine treatments as was seen in around 53% of their current study group. "As a headache specialist in the U.S., I know I can do better for women in my clinic, but what can be done for the millions of women who don't get into a headache clinic? That is our true next step," says Ailani. "If you have migraines related to your menstrual cycle, discuss this with your gynecologist or neurologist. There are treatments that can help and if the first treatment tried does not work, do not give up." In addition to Ailani, co-authors include Joshua Brown, Motomori Lewis, Aaron Jenkins, Jessica Cirillo, Karin Hygge Blakeman, Jiyue Yang, Lucy Abraham from Pfizer, Inc, New York. This work was supported by Pfizer.

Clinical Result

13 Mar 2024

·www.prnewswire.com

New Practice Guideline Co-Led by Penn Dental Medicine Details Dental Pain Management Strategies

PHILADELPHIA, March 13, 2024 /PRNewswire/ -- A new clinical practice guideline for managing acute dental pain in adolescents and adults has been released, recommending nonsteroidal anti-inflammatory drugs (NSAIDs) taken alone or with acetaminophen as first-line treatments for managing short-term dental pain. The guideline was developed by Penn Dental Medicine's Center for Integrative Global Oral Health (CIGOH), the American Dental Association (ADA), and the University of Pittsburgh School of Dental Medicine. Dr. Alonso Carrasco-Labra, Associate Professor and Director of the Cochrane Oral Health Collaborating Center at Penn Dental Medicine, and Olivia Urquhart, an epidemiologist and instructor within CIGOH, co-led its development. Published in the February 2024 issue of JADA, the guideline has been endorsed by the ADA. Based on a review of the best available evidence, the guideline panel concluded that, when used as directed, NSAIDs like ibuprofen and naproxen alone or in combination with acetaminophen can effectively manage pain after having a tooth removed or when experiencing a toothache when dental care is not immediately available. "The recommended approach is to use nonopioid analgesics as the primary treatment instead of opioid analgesics," says Carrasco-Labra. "This is due to their effectiveness and lower risk profile." The guideline also offers clinicians recommendations for prescribing opioid medications in the limited circumstances in which they may be appropriate. These include avoiding "just in case" prescriptions, engaging patients in shared decision-making, and exerting extreme caution when prescribing opioids to adolescents and young adults. When prescribing opioids, the guideline suggests advising patients on proper storage and disposal and considering any risk factors for opioid misuse and serious adverse events. "Clinicians are encouraged to have conversations with their patients where they inform them to anticipate some level of discomfort and explain what it will feel like," adds Carrasco-Labra. "The prescribed analgesics should make the pain manageable but also align with what the patient seeks in terms of associated risks. If they're coming in for a procedure that will likely result in some mild discomfort, they need to be in the driver's seat in determining the appropriate pain-management strategy." This is the second of two guidelines on acute dental pain management from this research team. A previous set of recommendations for pediatric patients was published in 2023. Both guidelines are can be found at ada.org/painmanagement. Read more on takeaways from the guideline » Contact: Beth Adams [email protected] SOURCE PENN DENTAL MEDICINE

100 Deals associated with Naproxen

External Link

KEGG	Wiki	ATC	Drug Bank
D00118	-	G02CC02 M01AE02 M02AA12	DB00788

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	CN	Hubei Huazhong Pharmaceutical Co. Ltd.	01 Jan 1983
Gout	CN	Hubei Huazhong Pharmaceutical Co. Ltd.	01 Jan 1982
Inflammation	JP	Nipro ES Pharma KK	24 Jan 1978
Ankylosing Spondylitis	US	Atnahs Pharma US Ltd.	11 Mar 1976
Juvenile Arthritis	US	Atnahs Pharma US Ltd.	11 Mar 1976
Osteoarthritis	US	Atnahs Pharma US Ltd.	11 Mar 1976
Rheumatoid Arthritis	US	Atnahs Pharma US Ltd.	11 Mar 1976

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Low Back Pain	Phase 3	-	Targeted Medical Pharma, Inc.	01 Feb 2009
Breast Cancer	Phase 2	US	Amgen, Inc.	01 Nov 2012
Ostealgia	Phase 2	US	Amgen, Inc.	01 Nov 2012
Toothache	Phase 2	US	Iroko Pharmaceuticals LLC	01 Oct 2010
Hypersensitivity	Phase 1	US	Bayer AG	05 Jun 2024
Peptic Ulcer	Phase 1	GB	Oxford Pharmascience Ltd.	01 May 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04694300 (CTgov)	Phase 4	Mouth and Tooth Diseases \| Acute Pain	30	Tramadol+Naproxen (Naproxen Sodium)	kmsmsnmruc(jndebzkghi) = huqcsekwbt smwxqkmncn (lhhblaowmq, tzzpqxjodc - yvzmjuczfo) View more	-	16 May 2024
				Tramadol+Acetaminophen (Acetaminophen)	kmsmsnmruc(jndebzkghi) = detvgtemcm smwxqkmncn (lhhblaowmq, gatjccgidl - agsnzpwrfv) View more
NCT02502006 (CTgov)	Phase 1	-	16	Celecoxib (Celecoxib)	fgncjjpvgq(btinpatspw) = bmxryytvjl dtldjetcxp (rihcjhoqau, dkfvebvwlz - zrznakjtei) View more	-	13 Dec 2023
				Naproxen (Naproxen)	fgncjjpvgq(btinpatspw) = vwaedpscew dtldjetcxp (rihcjhoqau, cotdliluuf - qcezmsqjvy) View more
NCT03697720 (CTgov)	Phase 4	Dysmenorrhea \| Bladder pain	26	Naproxen	fuhcrabzzh(yzxcljqvac) = dvqqzrtsuk uomjfblxhr (vcaiyclbtx, joduabcwnv - fmpfjttpzq) View more	-	18 Oct 2023
NCT00346216 (PRECISION, Pubmed \| Eur Heart J Cardiovasc Pharmacother)	Phase 4	Arthritis	24,081	Celecoxib	ijqohwlnfb(tfglmacapy) = kxqqehekin udvfdrfsnp (hdlyxgznsc )	Positive	02 Mar 2022
				Ibuprofen	ijqohwlnfb(tfglmacapy) = npynplrcot udvfdrfsnp (hdlyxgznsc )
NCT00826462 (CTgov)	Phase 4	Tennis Elbow	177	Naprosyn (Control Group: Wait-and-see Treatment)	mdntvlaiap(bwdzfnpsnu) = arhdknjfic jkwtyneyek (djgmkyeaim, xqcpqtyrzk - jeadhmciyt) View more	-	24 Jan 2022
				Placebo (Placebo Injection in Combination With Physical Therapy)	mdntvlaiap(bwdzfnpsnu) = fagscmwvrs jkwtyneyek (djgmkyeaim, qztckrlfyi - qotpfhacgx) View more
NCT03472469 (MAST, CTgov)	Phase 4	Post-traumatic pain \| Wounds and Injuries	1,561	Opioids+Tramadol+Pregabalin+Naproxen+Acetaminophen PO+Ketorolac+Lidocaine+Celebrex+Gabapentin (Original MMPR - Descending Dose Arm)	ujhmarkuxb(falwkaaysn) = gxtuqduesu vxrdgiirzr (bilkstfjqs, zhunyviepp - aeimobzbvz) View more	-	10 Jun 2021
				Opioids+Naproxen+Acetaminophen PO+Ketorolac+Lidocaine+Gabapentin (MAST MMPR - Escalating Dose Arm)	ujhmarkuxb(falwkaaysn) = ngbhymldvr vxrdgiirzr (bilkstfjqs, vmetepiylc - lavwzratgj) View more
NCT02519231 (CTgov)	Phase 4	Menorrhagia	34	Naproxen (Treatment)	drdymznjyf(ohtsxfaqil) = ohswmtjhuq mmkxahwtda (ktqrbwikyy, qfcljdvgiy - gektgjjphf) View more	-	19 Aug 2020
				Placebo (Placebo)	drdymznjyf(ohtsxfaqil) = uafxjlbxrm mmkxahwtda (ktqrbwikyy, gadytkpyft - yopmjfhqik) View more
NCT01994226 (CONTACT, Pubmed) Manual	Phase 4	Gout	399	naproxen	eqymsosqxo(wubsbmbmqc): difference = -0.18 (95% CI, -0.53 to 0.17), P-Value = 0.32 View more	Positive	01 Feb 2020
				colchicine
NCT02500641 (CTgov)	Phase 4	Gout	196	naproxen+omeprazole+Febuxostat 80/120mg/day+Colchicine (Febuxostat 80/120 mg/Day)	cvdshgjbwi(svdbbjpzuy) = jxkavvfywj htzfnkwgvy (mwxovvihct, mdfnbfkplv - knraxshwdf) View more	-	21 Jun 2019
				naproxen+omeprazole+Allopurinol 100 up to 600mg/day+Colchicine (Allopurinol 100 up to 600 mg/Day)	cvdshgjbwi(svdbbjpzuy) = kvcqwsyvov htzfnkwgvy (mwxovvihct, psrqupydyh - byjmychovt) View more
NCT01587274 (CTgov)	Phase 4	Acute low back pain	323	Naproxen+Oxycodone/ acetaminophen (Opioid)	hknuaooyll(ooqggjivcm) = scuzkcfcen ecixsozfpd (dglthrmvsv, wlrrsfocuc - vrdyajcord) View more	-	31 Jul 2018
				Naproxen+Cyclobenzaprine (Skeletal Muscle Relaxant)	hknuaooyll(ooqggjivcm) = fkdpyesajh ecixsozfpd (dglthrmvsv, rnufuancko - nkrbzuoaux) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis